Table 2.
Clinical and Immunological Characteristics of Study Participants
| Variables | Number (%) | |
|---|---|---|
| CTX prophylaxis | Yes | 105 (65.63) |
| No | 55 (34.37) | |
| INH prophylaxis | Yes | 57 (35.62) |
| No | 103(64.38) | |
| TB treatment history | Yes | 108(67.50) |
| No | 52(32.50) | |
| Type of TB | Pulmonary | 49 (45.37) |
| Disseminated | 29 (26.85) | |
| Unknown | 30 (27.78) | |
| Clinical stage (WHO) | Stage I | 13(8.12) |
| Stage II | 45 (28.13) | |
| Stage III | 72 (45) | |
| Stage IV | 30 (18.75) | |
| Eligibility reason to HAART | CD4+ count | 55 (34.40) |
| Clinical | 19 (11.90) | |
| CD4+ count & clinical | 86 (53.70) | |
| Mean time on HAART (in months) | 49.13±17.09 | |
| Median duration with HIV (in months) | 74.75 (IQR: 57.23–104.63) | |
| Base line CD4+ count (cells/µL) | Median (IQR) | 182.00 (104.53–262.4) |
| <200 | 97 (60.63) | |
| 200 −349 | 49 (30.62) | |
| 350 – 499 | 10 (6.25) | |
| ≥500 | 4 (2.5) | |
| Time elapsed from diagnosis to HAART initiation (in months) | Within the same month | 62 (38.75) |
| 1–24 | 64 (40) | |
| ≥24 | 44 (21.25) | |
| Functional Status | Working | 143(89.37) |
| Ambulatory | 17 (10.63) | |
| HAART Regimen | Nevirapine based | 59 (36.88) |
| Efavirenz based | 89 (56.25) | |
| Second line | 11 (6.87) | |
| Prior regimen change | Yes | 100(62.5) |
| No | 60(37.5) | |
| NCD comorbidity | Hypertension | 22 (13.75%) |
| Diabetes | 19 (11.88) | |
| Cardiac (Heart failure) | 7 (4.37) | |
| Asthma/COPD# | 6 (3.75) | |
| Mental Illness | 3 (1.88) | |
| Epilepsy | 3 (1.88) | |
| Multimorbidity** | 20 (12.50) | |
Notes: #Only one COPD patient included; **co-occurrence 2 or more disease together.
Abbreviations: CTX, Cotrimoxazole; INH, Isoniazid; TB, Tuberculosis; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; SD, Standard Deviation; CD4+, Cluster Differentiation, HAART, Highly Active Antiretroviral Therapy; COPD, chronic obstructive pulmonary disease; NCD, Non-communicable disease.